Миокардиальные цитопротекторы: клинико-фармакологические подходы к применению при ишемической болезни сердца

1. Шальнова С.А., Деев А.Д., Карпов Ю.А. Артериальная гипертония и ишемическая болезнь сердца в реальной практике врача-кардиолога. Кардиоваск. тер. и профил. 2006; 1: 73–80.
2. Крюков Н.Н., Качковский М.А., Бабанов С.А., Вербовой А.Ф. Справочник терапевта. Ростов-на-Дону: Феникс, 2013.
3. Косарев В.В., Бабанов С.А. Клиническая фармакология лекарственных средств, применяемых при сердечно-сосудистых заболеваниях. Самара: Офорт, 2010.
4. Бабанов С.А. Распространенность табакокурения среди городского населения Самары и факторы, ее определяющие. Терапевт. архив. 2008; 80 (1): 69–74.
5. Косарев В.В., Бабанов С.А., Вербовой А.Ф. Справочник клинического фармаколога. Ростов-на-Дону: Феникс, 2011.
6. Пархоменко А.Н. Жизнеспособный миокард и кардиоцитопротекция: возможности метаболической терапии при острой и хронической формах ишемической болезни сердца. Укр. мед. часопис. 2001; 3 (23): 5–11. http://www.umj.com.ua/pdf/23/umj_23_1157.pdf
7. Diaz R, Paolasso E, Piegas L et al. Metabolic modulation of acute myocardial infarction: The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 1998; 98 (21): 2227–34.
8. Hess ML, Okabe E, Poland J et al. Glucose, insulin, potassium protection during the course of hypothermic global ischemia and reperfusion: a new proposed mechanism by the scavenging of free radicals. J Cardiovasc Pharmacol 1983; 5 (1): 35–43.
9. Оковитый С.В. Клиничеcкая фармакология антигипоксантов. ФАРМиндекс–Практик, 2004; (Вып. 6): 30–9.
10. Kantor PF, Lucien A, Kozak R et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3–=-ketoacyl coenzyme A thiolase. J Circ Res 2000; 86, 5: 580–8.
11. Sakai K, Fukushi Y, Abiko Y. Inhibitory effect of trimetazidine on utilization of myocardial glycogen during coronary ligation in dogs. Pharmacology 1986; 32 (2); 72–3.
12. De Leiris J, Boucher F. Rationale for trimetazidine administration in myocardial ischaemia–reperfusion syndrome. Eur Heart J 1993; 14 (Suppl. G): 34–40.
13. Perletti G, Monti E, Paracchini L et al. Effect of trimetazidine on early and delayed doxorubicin myocardial toxicity. Arch Int Pharmacodyn Ther; 302: 280–9.
14. Renaud JF. Internal pH, Na+, and Ca2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther 1988; 1: 677–86.
15. Hisatome I, Ishiko R, Tanaka Y et al. Trimetazidine inhibits Na+, K(+)–ATPase activity, and overdrive hyperpolarization in guinea–pig ventricular muscles. Eur J Pharmacol 1991; 195: 381–8.
16. Sentex E, Sergiel JP, Lucien A et al. Trimetazidine increases phospholipid turnover in ventricular myocyte. Mol Cell Biochem 1997; 175: 153–62.
17. Grynberg A. Rale des lipides membranaires dans la cytoprotection myocardique. Arch Mal Coeur Vaiss 2000; 93: 175–82.
18. Libersa C, Honore E, Adamantidis M et al. Effets de la trimitazidine sur un module d’ischemie myocardique in vitro. Presse Med 1986; 15: 1765–69.
19. Fantini E, Demaison L, Sentex E et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994; 26: 949–58.
20. Devynck MA, Le Quan Sang KH, Joulin Y et al. Acute membrane effects of trimetazidine in human platelets. Eur J Pharmacol 1993; 245: 105–10.
21. Astarie-Dequeker C, Joulin Y, Devynck MA. Inhibitory effect of trimetazidine on thrombin–induced aggregation and calcium entry into human platelets. J Cardiovasc Pharmacol 1994; 23: 401–7.
22. Belcher PR, Drake-Holland AJ, Hynd JW et al. Effects of trimetazidine on in vivo coronary arterial platelet thrombosis. Cardiovasc Drugs Ther 1993; 7: 149–57.
23. Williams FM, Tanda K, Kus M et al. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993; 22: 828–33.
24. Fabiani JN, Farah B, Vuilleminot A et al. Chromosomal aberrations and neutrophil activation induced by reperfusion in the ischaemic human heart. Eur Heart J 1993; 14 (Suppl. G): 12–7.
25. Kowalski J, Pawlicki L, Baj Z et al. Effect of trimetazidine on biological activity of neutrophils in patients with transient myocardial ischemia induced by exercise testing. Pol Merkuriusz Lek 2000; 9: 548–51.
26. Kajstura J, Liu Y, Baldini A et al. Coronary artery constriction in rats: necrotic and apoptotic myocyte death. Am J Cardiol 1998; 82 (5A): 30K–41K.
27. Goncalves LM. Left ventricular dysfunction and cytoprotection. Rev Port Cardiol 2000; 19 (Suppl. 5): V21–24.
28. Timour Q, Harpey C, Durr F et al. Is the antianginal action of trimetazidine independent of hemodinamical changes? Cardiovasc Drugs Ther 1991; 5: 1043–44.
29. Passeron J. Efficacity de la trimetazidine dans I’angor d’effort stable de l’insuffisant coronarien chronique. Etude а double insu contre placebo. Presse Med 1986; 16 (15): 1775–8.
30. Marzilli M, Klein W. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis 2003; 14: 2171–9.
31. Sellier P, Audouin P, Payen B et al. Acute effects of trimetazidine evaluated by exercize testing. Eur J Clin Pharmacol 1987; 33: 205–7.
32. Michaelides A, Vyssoulis G, Bonoris P et al. Beneficial effects of trimetazidine in men with stable angina under beta-blocker treatment. Cur Ther Res 1989; 3–7.
33. Michaelides A, Spiropoulos K, Dimopoulus K et al. Antianginal efficacy of the combination of trimetazidine–propranolol compered with isosorbide dinitrate–propranolol in patients with stable angina. Clin Drug Invest 1997; 13: 116–122.
34. César L, Gowdak L, Mansur A. The metabolic treatment of patients with coronary artery disease: effects on quality of life and effort angina. Curr Pharm Des 2009; 15 (8): 841–9.
35. Никитин А.В., Гостева Е.В., Васильева Л.В. Опыт применения препарата Римекор у больных стенокардией и хронической сердечной недостаточностью. Cons. Med. 2012; 14 (10): 4–8.
36. Detry L, Sellier P, Pennaforte S et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994; 37: 279–88.
37. Detry L, Leclerc P. On behalf of the Trimetazidine European Multicenter Study Group. Trimetazidine European multicenter study versus propranolol in stable angina pectoris: contribution of Holter electrocardiographic ambulatory monitoring. Am J Cardiol 1995; 76: 813–11B.
38. Levy S. Intirkt de l’association de la trimetazidine (vastarel 20 mg) au diltiazem (tildiem 60 mg) dans l’angor d’effort stable. Etude multicentrique а double insu contre placebo. Ann Cardiol Angeiol (Paris) 1995; 44: 203–12.
39. Manchanda SC, Krishnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997; 78: 353–7.
40. Szwed H, Sadowski Z, Pachocki R et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL–1. J Cardiovasc Drugs Ther 1999; 13: 217–22.
41. Жарова Е.А., Лепахин В.К., Фитилев С.Б. и др. Триметазидин в комбинированной терапии стенокардии напряжения. Сердце. 2002; 4.
42. Meneveau N, Khalife K, Louis J et al. Free radicals, thrombolytic therapy and myocardial infarction: results of the EMIP–FR angiography substudy. Eur Heart J 1997; 18: 171.
43. Di Pasquale P, Lo Verso P, Bucca V et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short–term and long–term results. J Cardiovasc Drugs Ther 1999; 13: 423–8.
44. Papadopoulos CL, Kanonidis IE, Kotridis PS et al. The effect of trimetazidine on reperfusion arrhythmias in acute myocardial infarction. Int J Cardiol 1996; 55: 137–42.
45. Brottier L, Barat JL, Combe C et al. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 1990; 11: 207–12.

В.В.Косарев, С.А.Бабанов

ГБОУ ВПО Самарский государственный медицинский университет Минздрава РФ